July 11 (Reuters) - Shares of Glenmark Pharmaceuticals GLEN.NS jumped 10% in early trade on Friday, a day after a unit of the Indian drugmaker signed an exclusive licensing deal with U.S. peer AbbVie ABBV.N for its cancer treatment.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.